Ocera Therapeutics (Nasdaq:OCRX) today announced that it has entered into a Technology Transfer and License Agreement with the Roche Group, including the Research and Early Development arms of both Genentech and Roche, for rights to its ...
Tags: Ocera Therapeutics, Roche, Macrocyclic Template Chemistry
NovelMed Therapeutics has received a combined $1.43m small business innovation research (SBIR) grant from the National Institutes of Health (NIH) to further develop its anti-complement antibody for orphan disease. The company will use the ...
Second Sight Medical Products has secured Medicare coverage for its Argus II retinal prosthesis system (Argus II) designed to treat the patients affected with blindness from the untreatable orphan disease retinitis pigmentosa in both the US ...
Tags: Government Funding, Medicine
Daiichi Sankyo Company has opened the Orphan Disease Treatment Institute office inside the Daiichi Sankyo Shinagawa R&D center. Innovation Network Corporation of Japan, a fund managed by Mitsubishi UFJ Capital, and Daiichi Sankyo have ...
Tags: Daiichi Sankyo, Orphan Disease Treatment, Orphan Disease
The European Commission (EC) has granted a €6m grant to the "FIGHT HLH" consortium of institutions to support clinical testing of NovImmune's anti-interferon gamma drug candidate, NI-0501. The FIGHT HLH consortium lead by NovImmune ...
Shire and Boston Children's Hospital have formed a three-year, broad research collaboration to develop new therapies to treat rare pediatric diseases. As part of the agreement, Shire will make an initial upfront payment to Boston ...
Tags: pediatric diseases, Children's Hospital, new therapies
European Medicines Agency's (EMA) Committee for Orphan Medicinal Products has announced positive opinion for granting orphan disease designation to Aspireo Pharmaceuticals' Somatoprim for the treatment of acromegaly. Somatoprim, the ...